Evidence map›Paper›PMID 35994578›Full record

ArticleAIDS education and prevention : official publication of the International Society for AIDS Education2022

Acceptability of PC-1005 Gel Administered Rectally to HIV-1 Seronegative Adults at Three Different Volume Levels (MTN-037).

José A Bauermeister, Ryan C Tingler, Ken Ho, Rachel Scheckter, Tara McClure, Jontraye Davis, Jeanna Piper, Barbara A Friedland, Stacey Edick, Mei Song and 3 more

Abstract readClinical Trial, Phase I
In one paragraph

Article in AIDS education and prevention : official publication of the International Society for AIDS Education, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

José A BauermeisterUniversity of Pennsylvania, Philadelphia, Pennsylvania.
Ryan C TinglerUniversity of Pennsylvania, Philadelphia, Pennsylvania.
Ken HoUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Rachel ScheckterFHI 360, Durham, North Carolina.
Tara McClureFHI 360, Durham, North Carolina.
Jontraye DavisFHI 360, Durham, North Carolina.
Jeanna PiperDivision of AIDS/NIAID/NIH, Bethesda, Maryland.
Barbara A FriedlandPopulation Council, Center for Biomedical Research, New York, New York.
Stacey EdickUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Mei SongMicrobicide Trials Network, Pittsburgh, Pennsylvania.
Yuqing JiaoFred Hutchinson Cancer Research Center, Seattle, Washington.
Craig W HendrixJohns Hopkins University School of Medicine, Baltimore, Maryland.
Craig HoesleyUniversity of Alabama at Birmingham, Birmingham, Alabama.

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
University of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS P30 AI036219NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069494NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

Multipurpose prevention technologies (MPT) have been increasingly researched for their dual-purpose preventative properties against HIV and other STIs. The acceptability of PC-1005, a topical MPT candidate, was explored among men and women participating in the MTN-037 Phase I trial at two U.S. sites (Pittsburgh, PA, and Birmingham, AL). We triangulated quantitative and qualitative assessments of the acceptability of three volumes (4 mL, 16 mL, 32 mL) of PC-1005 administered rectally (N = 12; 6 males, 6 females). Participants rated overall gel acceptability on a scale of 1-10, with a median of 7.17 (

Indexed as

HIV-1HIV InfectionsHIV SeropositivitySexually Transmitted DiseasesAdultFemaleHumansMaleHIV preventionmicrobicideMPTrectalsexually transmitted infections

Identifiers

PMID35994578
PMCPMC9924357

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.